CROI 2011: David Martin
David E. Martin, PharmD, Senior Vice President, drug development/regulatory affairs, Tobira Therapeutics, Manalapan, NJ
David discusses Tobira's new CCR5/CCR2 receptor antagonist, currently in phase 2b. He covers past and current work and special benefits to CCR2 relative to its inflammatory response and the expectations of development of a part of a viable regimen or a coforumulation (combination therapy), as its dose seems fit for this application.
To download an audio mp3 file, right-click here and choose "Save".